Trends of HIV-1 incidence with credible intervals in Sweden 2002-09 reconstructed using a dynamic model of within-patient IgG growth

International Journal of Epidemiology

Volumn 44, Issue 3, 2015, Pages 998-1006

  Romero Severson, Ethan Obie ^a   Lee petrie, Cody ^a   Ionides, Edward ^b   Albert, Jan ^c   Leitner, Thomas ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bayesian methods; BED assay; Bootstrapping; Differential misclassification; HIV; Incidence estimation

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ALGORITHM; BAYESIAN ANALYSIS; BIOMARKER; BOOTSTRAPPING; DISEASE INCIDENCE; EPIDEMIC; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; RECONSTRUCTION; SPATIOTEMPORAL ANALYSIS; SYMPTOM; TREND ANALYSIS;

ARTICLE; CD4 LYMPHOCYTE COUNT; ENZYME IMMUNOASSAY; EPIDEMIC; FEMALE; HOMOSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; OPTICAL DENSITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEROCONVERSION; SUSCEPTIBLE POPULATION; SWEDEN; VIRUS LOAD; BAYES THEOREM; BLOOD; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY; SEX DIFFERENCE; THEORETICAL MODEL;

STOCKHOLM [SWEDEN]; SWEDEN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BAYES THEOREM; BIOMARKERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INCIDENCE; MALE; MODELS, THEORETICAL; SEX FACTORS; SWEDEN;

EID: 84939612066     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyv034     Document Type: Article

References (40)

1. Sabin CA, Schwenk A, Johnson MA et al. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010;24:723-27.
2. Zoufaly A, An der Heiden M, Marcus U et al. Late presentation for HIV diagnosis and care in Germany. HIV Med 2012;13: 172-81. PubMed PMID: 22093171. Epub 2011/11/19. eng.
3. d'Arminio Monforte A, Cozzi-Lepri A, Girardi E et al. Late presenters in new HIV diagnoses from an Italian cohort of HIVinfected patients: prevalence and clinical outcome. Antivir Ther 2011;16:1103-12.
4. Centers for Disease Control and Prevention (CDC). Late HIV testing-34 states, 1996-2005. MMWR Morb Mortal Wkly Rep 2009;58:661-65.
5. Barnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A. HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis. Epidemiology 2010;2:685-97.
6. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 2004;42:2623-28.
7. Parekh BS, Hanson DL, Hargrove J et al. Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 2011;27:265-73.
8. Hall HI, Song R, Rhodes P et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-29.
9. Le Vu S, Pillonel J, Semaille C et al. Principles and uses of HIV incidence estimation from recent infection testing-a review. Eurosurveillance 2008;13. PubMed PMID: 18775292. Epub 2008/09/09. eng.
10. UNAIDS. Reference group on estimates modelling and projections. Statement on the use of the BED assay for the esitmation of HIV-1 incidence for surveillance or epidemic monitoring. Wkly Epidemiol Rec 2006;81:40.
11. Laeyendecker O, Brookmeyer R, Oliver AE et al. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses 2012;28:816-22.
12. Guy R, Gold J, Calleja JM et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 2009;9:747-59.
13. Sakarovitch C, Rouet F, Murphy G et al. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 2007;45:115-22.
14. Kim AA, McDougal JS, Hargrove J et al. Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses 2010;26:1051-61.
15. Hallett TB, Ghys P, Barnighausen T, Yan P, Garnett GP. Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One 2009;4:e5720.
16. Laeyendecker O, Brookmeyer R, Cousins MM, et al. HIV incidence determination in the United States: A multi-assay approach. J Infect Dis 2013;207:232-39.
17. Laeyendecker O, Kulich M, Donnell D et al. Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One 2013;8:e78818.
18. Sharma U, Schito M, Welte A et al. Novel biomarkers for HIV incidence assay development. AIDS Res Hum Retroviruses 2011;28:532-39.
19. Skar H, Albert J, Leitner T. Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests. PLoS One 2013;8:e60906.
20. Sommen C, Commenges D, Vu SL, Meyer L, Alioum A. Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence. Biometrics 2011;67:467-75.
21. Alaeus A, Leitner T, Lidman K, Albert J. Most HIV-1 genetic subtypes have entered Sweden. AIDS 1997;11:199-202.
22. Karlsson A, Bjorkman P, Bratt G et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012;7:e33484.
23. Hargrove JW, Humphrey JH, Mutasa K et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 2008;22:511-18.
24. McDougal JS, Parekh BS, Peterson ML et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006; 22:945-52.
25. Chevret S, Costagliola D, Lefrere JJ, Valleron AJ. A new approach to estimating AIDS incubation times: results in homosexual infected men. J Epidemiol Community Health 1992;46:582-86.
26. Leitner T, Halapi E, Scarlatti G et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 1993;15:120-26.
27. Murillo W, de Rivera IL, Parham L et al. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 2010;11:95-103.
28. Leitner T, Korber BT, Daniels M, Calef C, Foley B. HIV-1 subtype and circulating recombinant form (CRF) reference sequences. In: Leitner T, Foley B, Hahn B et al. (eds). HIV Sequence Compendium 2005. Los Alamos, NM: Theoretical Biology and Biophysics, Los Alamos National Laboratory, 2005.
29. Su Y-S, Gelman A, Hill J, Yajima M. Multiple imputation with diagnostics (mi) in R: opening windows into the black box. J Stat Software 2011;45:1-31.
30. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2003.
31. Sommen C, Alioum A, Commenges D. A multistate approach for estimating the incidence of human immunodeficiency virus by using HIV and AIDS French surveillance data. Stat Med 2009; 28:1554-68.
32. Sexton CJ, Costenbader EC, Vinh DT et al. Correlation of prospective and cross-sectional measures of HIV type 1 incidence in a higher-risk cohort in Ho Chi Minh City, Vietnam. AIDS Res Hum Retroviruses 2012;28:866-73.
33. Karita E, Price M, Hunter E et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 2007;21:403-08.
34. Arneborn M, Blaxhult A. Increase in the spread of human immunodeficiency virus in Sweden, 2007. Eurosurveillance 2008 Mar 27;13(13). PubMed PMID: 18445430. Epub 2008/05/01. eng.
35. Skar H, Axelsson M, Berggren I et al. Dynamics of two separate but linked HIV-1 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland. J Virol 2011; 85:510-18.
36. InfCare. 2012 Yearly Report. [In Swedish.] Stockholm: Karolinska Institute, 2012.
37. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010;50(Suppl 3):S85-95.
38. Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI. Estimating HIV incidence in the United States from HIV/AIDS surveillance data and biomarker HIV test results. Stat Med 2008; 27:4617-33.
39. Duong YT, Qiu M, De AK et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012;7:e33328.
40. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I et al. Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. J Infect Dis 2012;206:756-64.